A 14 Weeks Prospective Pilot Study of the Headache Registry Program at Bangkok Hospital Medical Center

Article Sidebar

PDF
Published: Feb 20, 2014
DOI: https://doi.org/10.31524/bkkmedj.2014.02.005

Main Article Content

Nucharin Jindawong, BN, MBA
Kiratikorn Vongvaivanich, MD
Chakorn Chansakul, MD
Paweena Lertakyamanee, MD
Thitaree Yongprawat, BN, MSc
Laksamee Jarrat, BN
Arunrat Pokum, BSc

Abstract

OBJECTIVE: Obtain clinical information from headache patients to improve the management of headache patients at Bangkok Hospital Medical Center (BMC).


MATERIAL AND METHODS: Patients who visited the Comprehensive Headache Clinic at BMC from March to June 2013 were enrolled in this study. The follow-up period  is  14 weeks,  divided into 5 visits. At the first visit, patients complete   an initial assessment questionnaire including rating migraine disability, headache frequency and pain score. The diagnosis by our physicians is documented. The patient receives information about headaches and a treatment plan is discussed. The patients’ symptoms and any side effects are assessed from the 2nd to the 5th visits. This information, and any issues arising from taking medication, is evaluated to improve patient care delivered by the Comprehensive Headache Clinic.


RESULTS: Seventy patients were enrolled in the registry program. Eighty percent of the patients were female, with an average age of 36 ± 11 years. Migraine headache was the most common diagnosis (68.6%). Triptans were most commonly used for acute medication in 59% of the patients. Antiepileptics were most commonly prescribed as prophylactic treatment in 48% of patients. Patients with chronic migraine came in for follow up visits more regularly than patients with episodic headaches  (100%  vs.  71.1%  on  the 2nd visit, 100% vs. 65% on the 3rd visit, 100% vs. 11.1% on the 4th visit, and 94.7%, 0% on the 5th visit). The average pain score (NRS) dropped from 7 to 3 and the average headache frequency dropped from 3 to 2 times per week. These clinical outcomes showed a statistically significant improvement in patient quality of life.


CONCLUSION: The Headache Registry Program demonstrates a good adherence and compliance to treatment along with a significant reduction in the severity and frequency of headaches.

Article Details

How to Cite
1.
Jindawong N, Vongvaivanich K, Chansakul C, Lertakyamanee P, Yongprawat T, Jarrat L, Pokum A. A 14 Weeks Prospective Pilot Study of the Headache Registry Program at Bangkok Hospital Medical Center. BKK Med J [Internet]. 2014 Feb. 20 [cited 2024 Nov. 23];7(1):20. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/218730
Issue
Vol. 7 (2014): February
Section
Original Article

This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Diener HC, Gaul C, Jensen R, et al. Integrated headache care. Cephalalgia 2011;31:1039-47.
2. Matchar DB, Harpole L, Samsa GP, et al. The headache management trial: a randomized study of coordinated care. Headache 2008;48:1294-310.
3. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004;24:9-160.
4. Thai Association for the Study of Pain (TASP). Clinical Guidance for Acute Postoperative Pain Management. Edition 1, Bangkok.2011:20-3.
5. Sauro KM, Rose MS, Becker WJ, et al. HIT HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache 2010;50:383-95.
6. Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000;88:41-52.
7. Stewart WF, Lipton RB, Kolodner KB, et al. Reliability of the migraine disability assessment score in a population- based sample of headache sufferers. Cephalalgia 1999; 19:107-14.
8. Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task- force. Eur J Neurol 2009;16:968-81.
9. Silberstein SD, Lipton RB, Dodick DW. Wolff’s Headache and Other Head Pain. United States of America: Oxford University Press, Inc., 2008.
10. Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache- guideline of the EFNS headache panel. Eur J Neurol 2011;18:1115-21.
11. Vongvaivanich K. Update on Migraine Prophylaxis: Things that can help your migraine patients. Bangkok Med J 2013;5:50-60.
12. Vongvaivanich K. Migraine Headaches: Acute treatment in Thailand. Bangkok Med J 2013;2:95-104.
13. Rizzoli PB. Acute and preventive treatment of migraine.Continuum (Minneap Minn) 2012;18:764-82.
14. Silberstein SD, Holland S, Freitag F, et al. Quality Stan- dards Subcommittee of the American Academy of Neu- rology and the American Headache Society. Evidence- based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45.
15. Holland S, Silberstein SD, Freitag F, etal. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53.